Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization

Vaccine

Volumn 26, Issue 40, 2008, Pages 5107-5110

  Gudmundsdotter, Lindvi ^a,b   Boström, Ann Charlotte ^a,b   Burton, Catherine ^c   Rosignoli, Guglielmo ^c   Sandström, Eric ^d   Hejdeman, Bo ^d   Wahren, Britta ^a,b   Imami, Nesrina ^c   Gotch, Frances ^c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Chronic HIV 1 infection; Immunotherapy; rgp160; T cell phenotype

Indexed keywords

CD38 ANTIGEN; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE FUNCTION TEST; IMMUNOTHERAPY; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 50849140177     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.063     Document Type: Article

References (23)

1. Sandstrom E., and Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 353 9166 (1999) 1735-1742
2. + T cell homeostasis and function in advanced HIV disease. Science 277 5322 (1997) 112-116
3. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 5341 (1997) 1295-1300
4. McMichael A.J., and Rowland-Jones S.L. Cellular immune responses to HIV. Nature 410 6831 (2001) 980-987
5. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 182 3 (2000) 792-798
6. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192 1 (2000) 63-75
7. + lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci USA 86 6 (1989) 1993-1997
8. + T helper cell depletion occurs. J Clin Invest 82 6 (1988) 1908-1914
9. Musey L.K., Krieger J.N., Hughes J.P., Schacker T.W., Corey L., and McElrath M.J. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 180 2 (1999) 278-284
10. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 6754 (1999) 708-712
11. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101 11 (2003) 4260-4266
12. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3 11 (2002) 1061-1068
13. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410 6824 (2001) 106-111
14. Dorrell L., Yang H., Ondondo B., Dong T., di Gleria K., Suttill A., et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80 10 (2006) 4705-4716
15. Birx D.L., Loomis-Price L.D., Aronson N., Brundage J., Davis C., Deyton L., et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 phase II vaccine investigators. J Infect Dis 181 3 (2000) 881-889
16. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351 9112 (1998) 1320-1325
17. Centers for Disease Control and Prevention: 1994 revised guidelines for the performance of CD41 T-cell determinations in persons with human immunodeficiency virus (HIV) infections. MMWR Recomm Rep 1994;43:1-21.
18. Leandersson A.C., Bratt G., Hinkula J., Gilljam G., Cochaux P., Samson M., et al. Induction of specific T-cell responses in HIV infection. AIDS 12 2 (1998) 157-166
19. Hardy G.A., Imami N., Nelson M.R., Sullivan A.K., Moss R., Aasa-Chapman M.M., et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccine 5 (2007) 6
20. Levy Y., Durier C., Lascaux A.S., Meiffredy V., Gahery-Segard H., Goujard C., et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 20 3 (2006) 405-413
21. Hejdeman B., Leandersson A.C., Fredriksson E.L., Sandstrom E., Wahren B., and Bratt G. Better preserved immune responses after immunization with rgp160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up. HIV Med 4 2 (2003) 101-110
22. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 104 16 (2007) 6776-6781
23. Bisset L.R., Lung T.L., Kaelin M., Ludwig E., and Dubs R.W. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 72 3 (2004) 203-212